Clinical Trials

JBCRG-04TR (Blood sample)

Translational research on capecitabine as a postoperative adjuvant chemotherapy in breast cancer patients pathologically confirmed to have residual tumors after preoperative chemotherapy: Phase-III comparative study (JBCRG-04) (CREATE-X)

State
No longer recruiting/Ongoing trials

Objectives
The purpose of this study is to explore predictive factors for the treatment response or adverse effects of the multidrug chemotherapy containing anthracycline, taxane and/or capecitabine or hormonal therapy as adjuvant therapy and to investigate novel prognostic markers. In addition, metastatic tumor biological profile will be examined, which helps to understand biology of metastasis in breast cancer patients. In this research protocol, genotyping of patients using blood cells, somatic alterations of genome and epigenome, and gene expression profile in circulating tumor cells and tumor tissue samples will be examined.

Subjects

Endpoints

Trial Period

Lead Principal Investigator

Target Sample Size

Regimen

Source of Funding
Japan Breast Cancer Research Group(JBCRG)

Conference Presentation

Articles and Publications

UMIN-ID

jRCT

Memo

COI Disclosure

Clinical TrialsNext Page